...Russia's Human Stem Cells Institute said Russia approved Neovasculgen cambiogenplasmid to treat peripheral arterial disease (PAD). The company plans... ...PAD). The company plans to launch the plasmid vector containing the VEGF gene in 2Q12. Human Stem Cells Institute...
Human Stem Cells Institute , Moscow, Russia Business: Gene/Cell therapy, Supply/Service Date announced: 10/7/09 Type: IPO Shares: 15 million Price: RUB9-RUB11 Underwriter: CJSC Alor Invest Overallotment: TBD Note: A RUB10 price would raise RUB150 million ($5...
Human Stem Cells Institute (Moscow, Russia) plans to sell 15 million shares at RUB9-RUB11 in an IPO underwritten by CJSC Alor Invest. A RUB10 price would raise RUB150 million ($5 million). HSCI expects to have...
...Russia's Human Stem Cells Institute said Russia approved Neovasculgen cambiogenplasmid to treat peripheral arterial disease (PAD). The company plans... ...PAD). The company plans to launch the plasmid vector containing the VEGF gene in 2Q12. Human Stem Cells Institute...
Human Stem Cells Institute , Moscow, Russia Business: Gene/Cell therapy, Supply/Service Date announced: 10/7/09 Type: IPO Shares: 15 million Price: RUB9-RUB11 Underwriter: CJSC Alor Invest Overallotment: TBD Note: A RUB10 price would raise RUB150 million ($5...
Human Stem Cells Institute (Moscow, Russia) plans to sell 15 million shares at RUB9-RUB11 in an IPO underwritten by CJSC Alor Invest. A RUB10 price would raise RUB150 million ($5 million). HSCI expects to have...